Year: 2017
Type: review
Abstract: Brain aging is central to late-onset Alzheimer’s disease (LOAD), although the mechanisms by which it occurs at protein or cellular levels are not fully understood. Alzheimer’s disease is the most common proteopathy and is characterized by two unique pathologies: senile plaques and neurofibrillary tangles, the former accumulating earlier than the latter. Aging alters the proteostasis of amyloid- peptides and microtubule-associated protein tau, which are regulated in both autonomous and non-autonomous manners. Microglia, the resident phagocytes of the central nervous system, play a major role in the non-autonomous clearance of protein aggregates, whose function is significantly altered by aging and neurodegeneration. This is genetically supported by the association of microglia-specific genes, TREM2 and CD33, and late onset Alzheimer’s disease. Here, we propose that the functional characterization of microglia, and their contribution to proteopathy, will lead to a new therapeutic direction in Alzheimer’s disease research.
Source: Frontiers in Neuroscience
Institution: Boston University
Language: English
Subfield: Neurology
Field: Neuroscience
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,801
Awards: Novel TREM2 Reporter Platform for Drug Discovery, G4643942956, AGING AND EVENT-RELATED POTENTIALS, Training in Biomolecular Pharmacology, Exosome pathway as a novel therapeutic target of tauopathy, APOE and microglia-mediated progression in tau pathology in AD, Targeting the miR-155 and APOE-TREM2 pathways to restore dysfunctional microglia in Alzheimerâs disease
OpenAlex ID: W2773966647
